Nucleome Therapeutics logo.JPG
Nucleome Therapeutics announces publication of a novel method enabling 3D genome mapping at single base pair resolution in the journal Nature
June 10, 2021 02:00 ET | Nucleome Therapeutics
Nucleome Therapeutics announces publication of a novel method enabling 3D genome mapping at single base pair resolution in the journal Nature New method is being used by Nucleome to unlock the...
Nucleome Therapeutics logo.JPG
Nucleome Therapeutics announces appointment of Dr Jonathan Hepple as a Non-Executive Director to its Board
May 25, 2021 02:00 ET | Nucleome Therapeutics
Nucleome Therapeutics announces appointment of Dr Jonathan Hepple as a Non-Executive Director to its Board Nucleome’s unique technology platform has the potential to discover precision therapeutics...
logo.png
Allarity Therapeutics To Present a Dovitinib-DRP® e-Poster at the European Association for Cancer Research (EACR) 2021 Virtual Congress
April 29, 2021 10:31 ET | Allarity Therapeutics A/S
- Poster title: A novel drug response predictor (DRP®) mRNA biomarker for the multi tyrosine kinase inhibitor dovitinib - Poster provides new details of the DRP® companion diagnostic for dovitinib,...
LogoPressRelease.jpg
Fluidigm Announces Fourth Quarter and Full Year 2020 Financial Results
February 10, 2021 16:05 ET | Fluidigm Corporation
Fourth Quarter Total Revenue Increased 38 Percent to $44.6 million Fourth Quarter Product and Service Revenue Increased 26 Percent to $40.5 million Full Year Total Revenue Increased 18 Percent to...
LogoPressRelease.jpg
Fluidigm to Participate in BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference
February 04, 2021 16:02 ET | Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...
monopar.jpg
Monopar and NorthStar Announce Selection of uPRIT Candidate for Potential Treatment of Severe COVID-19
December 10, 2020 08:30 ET | Monopar Therapeutics Inc.
WILMETTE, Ill. and BELOIT, Wis., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) and NorthStar Medical Radioisotopes, LLC, which are jointly developing a urokinase...
SomaLogic Announces New Collaboration with FDA to Advance Biosimilar Development
October 29, 2020 10:00 ET | SomaLogic, Inc.
BOULDER, Colo., Oct. 29, 2020 (GLOBE NEWSWIRE) -- SomaLogic, Inc. announced today an agreement with the US Food and Drug Administration (FDA)’s Division of Applied Regulatory Science to evaluate the...
logo-alt.png
Global Non-alcoholic Steatohepatitis Biomarkers Market Accounted for US$ 556.6 Billion in 2019 and is Estimated to be US$ 8177.9 Billion by 2029 and is Anticipated to Register a CAGR of 31.3%
August 18, 2020 10:05 ET | PMI
Covina, CA, Aug. 18, 2020 (GLOBE NEWSWIRE) -- The report "Global Non-alcoholic Steatohepatitis Biomarkers Market, By Type (Serum Biomarkers, Hepatic Fibrosis Biomarkers, Apoptosis Biomarkers,...
monopar.jpg
Monopar Announces Plan to Advance Development of Novel Triage Test for Severe COVID-19 Utilizing its Patented Technology
August 12, 2020 08:30 ET | Monopar Therapeutics Inc.
WILMETTE, Ill., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) today announced its plan to develop a test to potentially triage COVID-19 patients into those likely versus...
LogoPressRelease.jpg
Fluidigm Announces Conference Call and Webcast of First Quarter 2020 Financial Results
April 20, 2020 16:06 ET | Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., April 20, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...